Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Atezolizumab

Drug and asset intelligence for Atezolizumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Stage
Development stage unavailable

Sponsor company

Roche →

Recent signals(2)

ClinicalJune 18, 2026

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

The RAPTOR trial is assessing the efficacy of adding radiation therapy to atezolizumab maintenance in extensive stage small cell lung cancer.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Colorectal Cancer →
Small Cell Lung Cancer →

Therapeutic areas

Colorectal Cancer →
Oncology →
Small Cell Lung Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.